A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome

This study aims to evaluate the effectiveness of interventional treatment guided by Intravascular Ultrasound (IVUS) compared to Digital Subtraction Angiography (DSA) in patients with Budd-Chiari Syndrome (BCS). Using a prospective, randomized controlled trial design, patients who meet the diagnostic criteria for BCS and are suitable for interventional treatment are randomly divided into the IVUS group and the DSA group. The IVUS group will undergo detailed assessment of vascular structure before interventional treatment to select the appropriate balloon for dilation, whereas the control group will make decisions based on DSA results. The primary endpoint of the study is the postoperative restenosis rate, while secondary endpoints include complications of interventional treatment, liver function, and patient survival rate. Successful implementation of this study will provide new technical means to optimize interventional treatment strategies for BCS, and help improve treatment outcomes and long-term prognosis for patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Budd-Chiari Syndrome Cardiovascular Diseases Digestive System Diseases Embolism and Thrombosis Liver Diseases Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Interventional Radiology, the Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221000, China

About this study

This study aims to establish a precise interventional diagnostic and therapeutic system for Budd-Chiari Syndrome (BCS) based on IVUS assistance by comparing it with conventional DSA-guided diagnosis and intervention. The goal is to improve diagnostic accuracy and treatment outcomes for complex and difficult BCS patients using IVUS technology, reduce the incidence of postoperative restenosis, and enhance long-term patient prognosis. Specific objectives include:

Enhance the diagnostic accuracy for BCS patients, particularly in determining the nature of vascular obstruction and assessing hemodynamic status.
Optimize the interventional treatment strategy for BCS, including the selection and implantation of balloons and stents, and reduce surgical complications.
Increase the patency rate of vessels after interventional treatment and lower the incidence of restenosis.
Establish a set of IVUS-based precise diagnosis and treatment processes for BCS, promoting the application and dissemination of IVUS technology in BCS diagnosis and treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age between 18 and 75 years.
Primary Budd-Chiari Syndrome (narrowing or occlusion of the inferior vena cava near the hepatic veins or hepatic vein openings).
Presence of membrane or short segment stenosis or occlusion suitable for balloon dilation (≤ 5 cm).
Child-Pugh score less than 13.
The patient or their authorized family member signs an informed consent form, voluntarily participating in the study and agreeing to follow-up.

Exclusion criteria

Prior interventional treatment.
Unfit for balloon dilation or stent placement (e.g., diffuse obstruction of the hepatic veins recommended for TIPS treatment, end-stage liver disease recommended for liver transplantation, etc.).
Coexisting severe heart disease (such as heart failure, severe arrhythmias), liver or kidney failure, severe infections, iodinated contrast agent allergy.
Coexisting hepatocellular carcinoma or other malignant tumors.
Pregnant or breastfeeding women.
Patients with a life expectancy of less than 1 year.
Patients unable to complete follow-up or cooperate with the study.

Treatment and study plan

Intravascular Ultrasound

Device

In the IVUS group, the diameter of the reference vessel (the normal segment of the artery distal to the occlusion) is measured using Intravascular Ultrasound (IVUS). Based on the IVUS measurements, an appropriate balloon is selected to dilate the occluded segment.

Digital Subtraction Angiography

Device

The DSA group patients will have the appropriate balloon dilation selected for the occluded segment based on the DSA measurement results.

Primary outcomes

Rate of Restenosis

Time frame: Follow-up and assessment will be conducted at 1 month, 3 months, 6 months, and 12 months post-surgery.

At the 1 month, 3 months, 6 months, and 12 months follow-up after surgery, vascular patency will be assessed through imaging examinations such as ultrasound, CT, or MRI, and the incidence of restenosis will be recorded to compare the treatment outcomes between the IVUS group and the DSA group

Sponsors and collaborators

Lead sponsor

The Affiliated Hospital of Xuzhou Medical University

Other

Registry information

Official study title

A Prospective Randomized Controlled Clinical Study on Interventional Treatment of Budd-Chiari Syndrome Guided by IVUS and DSA

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: May 7, 2025
Registry last updated: May 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed